Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSTVAC and Enzalutamide in mCRPC
NCT01867333Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2013
- Primary completion
- Sep 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rilimogene galvacirepvec in metastatic castration-resistant prostate cancer (mCRPC), sponsored by National Cancer Institute. Started Aug 2013; status: completed.
02
Drugs
rilimogene galvacirepvec
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01867333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867333.